Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Xi-Zhi Wen"'
Autor:
Fu-xue Huang, Jun-wan Wu, Xia-qin Cheng, Jiu-hong Wang, Xi-zhi Wen, Jing-jing Li, Qiong Zhang, Hang Jiang, Qiu-yue Ding, Xiao-feng Zhu, Xiao-shi Zhang, Ya Ding, Dan-dan Li
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAs a recognized highly immunogenic tumor, immune checkpoint blockades (ICB) have been widely used as a systemic treatment option for melanoma. However, only about half of treated patients could benefit from it in Caucasians, and only about
Externí odkaz:
https://doaj.org/article/5291d2152a944ee893c5f2e00d358611
Autor:
Xing Liu, Jing-jing Li, Ya Ding, Dan-dan Li, Xi-zhi Wen, De-sheng Weng, Jiu-hong Wang, Hang Jiang, Xiao-shi Zhang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The toxicity spectrum between Chinese and Caucasian patients with melanoma who were treated with BRAF inhibitors (BRAFi) may differ. The purpose of the present study was to assess the safety and tolerability of BRAFi and BRAFi-based combination thera
Externí odkaz:
https://doaj.org/article/3bc39f885d4743a6bbc1282db6981dad
Autor:
Ze-Xian Liu, Wei Xiao, Jing-Jing Zhao, Qiu-Zhong Pan, De-Sheng Weng, Yi Que, Xiao-Long Zhang, Xi-Zhi Wen, Bu-Shu Xu, Dong-Chun Hong, Tian-Hui Guo, Lu-Jun Shen, Wei-Jun Fan, Huo-Ying Chen, Hai-Rong Xu, Peng-Hui Zhou, Yi-Zhuo Zhang, Xiao-Hui Niu, Xing Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Background The advent of immune checkpoint therapy has been a tremendous advance in cancer treatment. However, the responses are still insufficient in patients with soft tissue sarcoma (STS). We aimed to identify rational combinations to increase the
Externí odkaz:
https://doaj.org/article/e988ecebac5347968984760e03511f4d
Autor:
Yao Wang, Jing-jing Li, Hong-jun Ba, Ke-feng Wang, Xi-zhi Wen, Dan-dan Li, Xiao-feng Zhu, Xiao-shi Zhang
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Immune checkpoint blockade of programmed cell death protein 1 (PD-1) had an impressive long-lasting effect in a portion of advanced-stage melanoma patients, however, this therapy failed to induce responses in several patients; how to increase the obj
Externí odkaz:
https://doaj.org/article/140871345f0849e8a051f45c16ac49d8
Autor:
Xi-zhi Wen, Qiu-zhong Pan, Bu-shu Xu, Wei Xiao, De-sheng Weng, Jing-jing Zhao, Hai-rong Xu, Zhen Huang, Xiao-hui Niu, Xing Zhang
Publikováno v:
Cancer chemotherapy and pharmacology. 89(2)
The repeated use of doxorubicin is limited due to dose-limiting cardiac toxicity. Pegylated liposomal doxorubicin (PEG-LD, Duomeisu) has a reduced cardiac toxicity. This phase I study aimed to investigate the maximum tolerated doses (MTDs) and dose-l
Publikováno v:
Aging (Albany NY)
The prognosis of melanoma patients is highly variable due to multiple factors conditioning immune response and driving metastatic progression. In this study, we have correlated the expression of immune-related lncRNAs with patient survival, developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::700b49918333bf8cd2954116afc966d1
https://avesis.deu.edu.tr/publication/details/1aa2d0e3-f0c5-4cad-9d3b-d2dc24f962ec/oai
https://avesis.deu.edu.tr/publication/details/1aa2d0e3-f0c5-4cad-9d3b-d2dc24f962ec/oai
Autor:
Jingjing Li, Yao Wang, Ya Ding, Xiao Shi Zhang, Xi Zhi Wen, Hong Jun Ba, Dan Dan Li, Ke Feng Wang
Publikováno v:
Melanoma Research. 27:469-476
Acral melanoma is a rare disease, but is common in Asia. Knowledge of its prognostic indicators is limited. Growing evidence indicates that inflammation plays a critical role in the development and progression of acral melanoma. We developed a novel
Autor:
Xi Zhi Wen, Xiaojun Wu, Rui Qing Peng, Wei Liu, Xing Zhang, Xiao Shi Zhang, Jingjing Li, Shu Guang Zhu, Dan Dan Li, Ya Ding, Bo Xie
Publikováno v:
Oncotarget
Calreticulin (CRT) exposure on the cell surface is essential for inducing immunogenic cell death by chemotherapy. Recent studies have shown conflicting effects of chemotherapy-induced autophagy on CRT exposure in cancer cells. Our data revealed that
Autor:
XING-YU FENG1,2, XI-ZHI WEN1,3, XIAO-JING TAN4,5, JING-HUI HOU1,6, YA DING1,3, KE-FENG WANG1,3, JUN DONG1,3, ZHI-WEI ZHOU1,2, YING-BO CHEN1,2 chenyb@sysucc.org.cn, XIAO-SHI ZHANG1,3 zhangxsh@sysucc.org.cn
Publikováno v:
Molecular Medicine Reports. 2015, Vol. 11 Issue 1, p658-664. 7p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.